IDNA vs XBI

IDNABiShares Genomics Immunology and Healthcare ETF

XBIAState Street SPDR S&P Biotech ETF

In short

IDNA Most biotech ETFs hand you the US biotech index. IDNA goes narrower and wider at once: about 50 companies from developed and emerging markets, picked around genomics, immunology and bioengineering.

XBI Biotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

IDNA The Fund seeks to track an index of developed- and emerging-market companies positioned to benefit from long-term growth and innovation in genomics, immunology, and bioengineering.

XBI The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

• IDNA The mandate is specific: an index of developed- and emerging-market companies tied to genomics, immunology and bioengineering, not a catch-all biotech basket.ishares.com
• 0.47% a year, a shade under the typical fund in its genomics-and-biotech peer group.
• About 50 holdings, so individual genomics and immunology names carry real weight instead of getting diluted inside a broad healthcare index.
• Running since 2019 under the iShares roof, and it stands in the upper half of its biotech and genomics peer group.

• XBI Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
• 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
• Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
• A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

• IDNA Concentration cuts both ways: about 50 stocks in one theme, so single-company clinical news lands harder here than in a broad healthcare fund.
• Smaller and less actively traded than the category's giants, so limit orders earn their keep. Emerging-market holdings add currency and local-market risk.
• Broad biotech index funds charge less, IBBQ at 0.19% and IBB at 0.44%; the extra basis points here buy the global genomics-and-immunology tilt.

• XBI Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comnasdaqomx.com
• Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
• One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

Full IDNA profile⁠

Full XBI profile⁠